275 related articles for article (PubMed ID: 7970124)
1. Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation.
Frémeaux-Bacchi V; Weiss L; Brun P; Kazatchkine MD
Nephrol Dial Transplant; 1994; 9(7):811-4. PubMed ID: 7970124
[TBL] [Abstract][Full Text] [Related]
2. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
[TBL] [Abstract][Full Text] [Related]
3. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
Hiramatsu M; Balow JE; Tsokos GC
J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
[TBL] [Abstract][Full Text] [Related]
4. Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity.
Frémeaux-Bacchi V; Weiss L; Demouchy C; May A; Palomera S; Kazatchkine MD
Nephrol Dial Transplant; 1994; 9(12):1747-50. PubMed ID: 7708258
[TBL] [Abstract][Full Text] [Related]
5. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.
Tanuma Y; Ohi H; Watanabe S; Seki M; Hatano M
Clin Exp Immunol; 1989 Apr; 76(1):82-5. PubMed ID: 2736802
[TBL] [Abstract][Full Text] [Related]
6. Autoantibody to the alternative pathway C3/C5 convertase and its anti-idiotypic response. A study in affinity.
Spitzer RE; Stitzel AE; Tsokos GC
J Immunol; 1992 Jan; 148(1):137-41. PubMed ID: 1727863
[TBL] [Abstract][Full Text] [Related]
7. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
Licht C; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
[TBL] [Abstract][Full Text] [Related]
8. Anti-factor B autoantibody in dense deposit disease.
Strobel S; Zimmering M; Papp K; Prechl J; Józsi M
Mol Immunol; 2010 Apr; 47(7-8):1476-83. PubMed ID: 20193965
[TBL] [Abstract][Full Text] [Related]
9. Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN).
Ohi H; Watanabe S; Fujita T; Yasugi T
Clin Exp Immunol; 1992 Sep; 89(3):479-84. PubMed ID: 1516262
[TBL] [Abstract][Full Text] [Related]
10. Detection of C3bBb-stabilizing activity (C3 nephritic factor) in the serum from patients with membranoproliferative glomerulonephritis.
Ohi H; Watanabe S; Fujita T; Seki M; Hatano M
J Immunol Methods; 1990 Jul; 131(1):71-6. PubMed ID: 2380570
[TBL] [Abstract][Full Text] [Related]
11. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
Tanuma Y; Ohi H; Hatano M
Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
[TBL] [Abstract][Full Text] [Related]
12. Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN).
Ohi H; Yasugi T
Clin Exp Immunol; 1994 Feb; 95(2):316-21. PubMed ID: 8306508
[TBL] [Abstract][Full Text] [Related]
13. Management of membranoproliferative glomerulonephritis type II with plasmapheresis.
Kurtz KA; Schlueter AJ
J Clin Apher; 2002; 17(3):135-7. PubMed ID: 12378549
[TBL] [Abstract][Full Text] [Related]
14. Identification of nephritic factor as an immunoglobulin.
Williams DG; Bartlett A; Duffus P
Clin Exp Immunol; 1978 Sep; 33(3):425-9. PubMed ID: 104814
[TBL] [Abstract][Full Text] [Related]
15. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
Ng YC; Peters DK
Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
[TBL] [Abstract][Full Text] [Related]
16. Human anti-idiotypic antibody responses to autoantibody against the alternative pathway C3 convertase.
Spitzer RE; Stitzel AE; Tsokos GC
Clin Immunol Immunopathol; 1990 Oct; 57(1):19-31. PubMed ID: 2394034
[TBL] [Abstract][Full Text] [Related]
17. A novel ELISA assay for the detection of C3 nephritic factor.
Seino J; vd Wall Bake WL; van Es LA; Daha MR
J Immunol Methods; 1993 Feb; 159(1-2):221-7. PubMed ID: 8445254
[TBL] [Abstract][Full Text] [Related]
18. On the origin and control of C3NeF.
Spitzer RE; Stitzel AE
In Vivo; 1988; 2(1):79-81. PubMed ID: 2979821
[TBL] [Abstract][Full Text] [Related]
19. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
20. Evidence that production of autoantibody to the alternative pathway C3 convertase is a normal physiologic event.
Spitzer RE; Stitzel AE; Tsokos GC
J Pediatr; 1990 May; 116(5):S103-8. PubMed ID: 2329411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
